Form 4: Stephanie O'Brien's Apellis Pharmaceuticals Stock Transactions

Stephanie O'Brien, a Director at Apellis Pharmaceuticals, reported a transaction involving 5,750 shares of common stock.

Summary

• Stephanie O'Brien, a Director at Apellis Pharmaceuticals, Inc., reported a transaction on April 6, 2026.
• The transaction involved the acquisition of 5,750 shares of common stock.
• These shares were distributed from a trust to an account held by O'Brien's spouse, with her beneficial ownership remaining unchanged.
• Following this transaction, O'Brien beneficially owns 5,750 shares indirectly through her spouse and 25,666 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it solely reports an insider stock transaction without providing company performance data or strategic updates.

Positives

• No change in beneficial ownership for Stephanie O'Brien, indicating no personal divestment or acquisition.
• Direct ownership of 25,666 shares by Stephanie O'Brien demonstrates continued commitment to the company.

Negatives

• The filing is a Form 4, which reports changes in beneficial ownership, and does not inherently contain positive or negative financial performance indicators for the company itself.

Risks

• The filing does not explicitly mention any risks.
• As a Form 4, it is focused on insider transactions and not on company-specific operational or market risks.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions and do not typically provide strategic insights into a company's performance or market position within the biopharmaceutical industry.

Related Party Transactions

• Distribution of shares from a trust to an account held by the reporting person's spouse.

Stakeholder Impact

• Shareholders: The transaction does not indicate a change in beneficial ownership for the reporting person, thus having no immediate impact on their stake or perceived insider confidence.
• Management: Standard reporting requirement for directors.

Next Steps

• No specific next steps are mentioned in this filing.

Key Dates

Keywords

Form 4, Insider Transaction, Apellis Pharmaceuticals, Stephanie O'Brien, Beneficial Ownership, Common Stock, Director